JUL 6, 2023

The MiniMed™ 780G system with Meal Detection™ technology* now available to Medicare beneficiaries

Orders will be processed immediately and shipments will start in the coming weeks

DUBLIN – July 6, 2023 – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today that its MiniMed™ 780G system with the new Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology‡ is now covered for all eligible Medicare and Medicare Advantage beneficiaries. Medtronic will begin processing orders immediately and will start shipments over the next few weeks to those with type 1 diabetes who meet eligibility criteria.



"Coming off the heels of a very exciting 83rd American Diabetes Association Scientific Sessions where we shared the latest real-world data on our MiniMed™ 780G system, we couldn't be more thrilled to expand access to our Meal Detection™ technology that's helping many individuals around the world achieve an average Time in Range exceeding 80 percent[1] when using recommended settings," said Que Dallara, EVP and President, Medtronic Diabetes. "We see people of all ages and from different therapies benefitting significantly from improved outcomes with the MiniMed™ 780G system. We attribute this to the easy-to-use design coupled with a powerful algorithm that provides coverage when life gets in the way – one that's designed for real life."

The MiniMed™ 780G system delivers automatic adjustments and corrections† to sugar levels every 5 minutes§ to provide coverage for when users occasionally forget to bolus or underestimate the number of carbs in their meal. It features the lowest target setting (as low as 100 mg/dL) in any automated insulin pump on the market§ to more closely mirror the average glucose of someone not living with diabetes.

"What's particularly compelling about the MiniMed™ 780G system is that it broadens eligibility to many more individuals interested in automated insulin delivery to help them achieve their diabetes management goals," said Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "Historically, there's been a stepwise approach towards prescribing pump therapy when certain criteria were met including the ability to carb count and use advanced technology. This approach is no longer relevant given the system's ability to overcome these challenges. We are very pleased that we're able to make this technology available to Medicare beneficiaries."

The MiniMed™ 780G system is approved in the U.S. for individuals with type 1 diabetes, 7 years and above. Visit www.medtronicdiabetes.com/780G to learn more about the system and to place your order.

About Medtronic Diabetes (www.medtronicdiabetes.com)

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.medtronic.com and follow @Medtronic on Twitter and LinkedIn.

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

§ Refers to SmartGuard™ feature. Individual results may vary.

**The extended wear infusion set can be worn for up to 7 days. Current infusion sets are recommended for up to 3 days of wear.

‡ Fingersticks required in manual mode & to enter SmartGuard™. If symptoms don't match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard™

1) Medtronic data on file: MiniMed™ 780G data uploaded voluntarily by 135 users in US, as of June 19, 2023. Results reflect users using recommended settings. Real-World clinical data presented here refer to MiniMed™ 780G system used in combination with Guardian™ sensor 3 and/or Guardian™ 4 sensor.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

https://news.medtronic.com/The-MiniMed-TM-780G-system-with-Meal-Detection-TM-technology-now-available-to-Medicare-beneficiaries